FDAsafety guidance66% confidence
FDA AP — LITFULO (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Pfizer; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA215830. Sponsor: PFIZER. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: RITLECITINIB TOSYLATE.
Supporting Context
- Therapeutic area
- Dermatology · JAK Inhibitor
- Sub-indication
- General
Related signal: FDA Approves Supplemental NDA for Pfizer's Ritlecitinib Tosylate (Litfulo)